{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:40:40Z","timestamp":1770435640065,"version":"3.49.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,15]]},"DOI":"10.1093\/cid\/cit069","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T07:04:40Z","timestamp":1360307080000},"page":"1382-1393","source":"Crossref","is-referenced-by-count":48,"title":["Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States"],"prefix":"10.1093","volume":"56","author":[{"given":"Mark H.","family":"Eckman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Talal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,2,7]]},"reference":[{"key":"key\n\t\t\t\t20170623051943_CIT069C1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"5 suppl 1","key":"key\n\t\t\t\t20170623051943_CIT069C2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170623051943_CIT069C4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200624070-00005","article-title":"Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies","volume":"24","author":"Wong","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"key\n\t\t\t\t20170623051943_CIT069C5","volume-title":"Hepatitis C: an epidemic for anyone","year":"2012"},{"key":"key\n\t\t\t\t20170623051943_CIT069C6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.25842","article-title":"Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection","volume":"56","author":"Gordon","year":"2012","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-127-10-199711150-00001","article-title":"Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C","volume":"127","author":"Bennett","year":"1997","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10320","article-title":"The cost-effectiveness of testing for hepatitis C in former injecting drug users","volume":"10","author":"Castelnuovo","year":"2006","journal-title":"Health Technol Assess"},{"key":"key\n\t\t\t\t20170623051943_CIT069C9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwf100","article-title":"Empirically calibrated model of hepatitis C virus infection in the United States","volume":"156","author":"Salomon","year":"2002","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jmv.10406","article-title":"Natural histories of hepatitis C virus infection in men and women simulated by the Markov model","volume":"70","author":"Tanaka","year":"2003","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C11","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2105\/AJPH.90.10.1562","article-title":"Estimating future hepatitis C morbidity, mortality, and costs in the United States","volume":"90","author":"Wong","year":"2000","journal-title":"Am J Public Health"},{"key":"key\n\t\t\t\t20170623051943_CIT069C12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.25510","article-title":"Economic model of a birth cohort screening program for hepatitis C virus","volume":"55","author":"McGarry","year":"2012","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence","volume":"31","author":"Chak","year":"2011","journal-title":"Liver Int"},{"key":"key\n\t\t\t\t20170623051943_CIT069C15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cgh.2010.09.014","article-title":"Increased mortality among persons infected with hepatitis C virus","volume":"9","author":"Omland","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jhep.2010.01.033","article-title":"Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study","volume":"53","author":"Omland","year":"2010","journal-title":"J Hepatol"},{"issue":"4 Pt 1","key":"key\n\t\t\t\t20170623051943_CIT069C17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/gut.52.4.574","article-title":"Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study","volume":"52","author":"Wright","year":"2003","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170623051943_CIT069C19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170623051943_CIT069C20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1365-2893.2002.00340.x","article-title":"Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model","volume":"9","author":"Deuffic-Burban","year":"2002","journal-title":"J Viral Hepat"},{"issue":"5 suppl 1","key":"key\n\t\t\t\t20170623051943_CIT069C21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"Marcellin","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C22","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.510230607","article-title":"The long-term pathological evolution of chronic hepatitis C","volume":"23","author":"Yano","year":"1996","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C25","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C26","first-page":"1","article-title":"United States Life Tables, 2007","author":"Arias","year":"2011"},{"key":"key\n\t\t\t\t20170623051943_CIT069C27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"issue":"5 suppl 1","key":"key\n\t\t\t\t20170623051943_CIT069C28","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gut.47.1.131","article-title":"Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death","volume":"47","author":"Degos","year":"2000","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170623051943_CIT069C30","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.510250629","article-title":"Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study","volume":"25","author":"Figueras","year":"1997","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/gast.1996.v110.pm8536853","article-title":"A longitudinal analysis of hepatitis C virus replication following liver transplantation","volume":"110","author":"Gane","year":"1996","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1432-2277.2002.tb00132.x","article-title":"Liver transplantation and hepatitis C","volume":"15","author":"Willems","year":"2002","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20170623051943_CIT069C33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.20083","article-title":"MELD score as a predictor of pretransplant and posttransplant survival in OPTN\/UNOS status 1 patients","volume":"39","author":"Kremers","year":"2004","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C35","article-title":"Time to transplant, 2000 to 2009, new liver waiting list registrations, Table 15.2.","author":"Scientific Registry of Transplant Recipients","year":"2009"},{"key":"key\n\t\t\t\t20170623051943_CIT069C36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000658-200010000-00004","article-title":"Long-term survival after liver transplantation in 4,000 consecutive patients at a single center","volume":"232","author":"Jain","year":"2000","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t20170623051943_CIT069C37","article-title":"Unadjusted patient survival, deceased donor liver transplants survival at 3 months, 1 year, 3 years, and 5 years, Table 9.14a.","year":"2009","journal-title":"US Department of Health and Human Services."},{"key":"key\n\t\t\t\t20170623051943_CIT069C38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.89.1.14","article-title":"Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994","volume":"89","author":"McQuillan","year":"1999","journal-title":"Am J Public Health"},{"key":"key\n\t\t\t\t20170623051943_CIT069C39","first-page":"1","article-title":"Surveillance for acute viral hepatitis\u2014United States, 2005","volume":"56","author":"Wasley","year":"2007","journal-title":"MMWR Surveill Summ"},{"key":"key\n\t\t\t\t20170623051943_CIT069C40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C41","volume-title":"Screening for hepatitis C virus infection. Systematic evidence review","author":"Chou","year":"2004"},{"key":"key\n\t\t\t\t20170623051943_CIT069C42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hep.510240301","article-title":"Detection of common hepatitis C virus subtypes with a third-generation enzyme immunoassay","volume":"24","author":"Huber","year":"1996","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C","volume":"136","author":"Falck-Ytter","year":"2002","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1478-3231.2009.02156.x","article-title":"Hepatitis C treatment completion rates in routine clinical care","volume":"30","author":"Butt","year":"2009","journal-title":"Liver Int"},{"key":"key\n\t\t\t\t20170623051943_CIT069C45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1572-0241.2002.05439.x","article-title":"Limited success of HCV antiviral therapy in United States veterans","volume":"97","author":"Cawthorne","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00004836-200203000-00015","article-title":"A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection","volume":"34","author":"Muir","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C48","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C50","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C51","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C52","article-title":"Telaprevir-based HCV treatment benefits all IL28B genotypes.","volume-title":"Digestive Disease Week, 10 May 2011.","author":"Helwick","year":"2011"},{"key":"key\n\t\t\t\t20170623051943_CIT069C53","first-page":"401A","article-title":"et al. Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved a extended rapid virological response: final results of phase 3 ILLUMINATE study. Abstract LB-2","volume":"52","author":"Sherman","year":"2010","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective","volume":"17","author":"McAdam-Marx","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"key\n\t\t\t\t20170623051943_CIT069C55","volume-title":"Red Book Online","year":"2012"},{"key":"key\n\t\t\t\t20170623051943_CIT069C56","article-title":"Clinical laboratory fee schedule\u20142011 clinical laboratory fee schedule file.","volume-title":"Hyattsville","author":"Centers for Medicare and Medicaid Services","year":"2011"},{"key":"key\n\t\t\t\t20170623051943_CIT069C57","article-title":"Physician fee schedule\u20142011 national physician fee schedule relative value file.","volume-title":"Hyattsville","author":"Centers for Medicare and Medicaid Services","year":"2011"},{"key":"key\n\t\t\t\t20170623051943_CIT069C58","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: a systematic review","volume":"28","author":"McLernon","year":"2008","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t20170623051943_CIT069C59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C60","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of utilities for chronic hepatitis C from SF-36 scores","volume":"100","author":"Thein","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C62","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170623051943_CIT069C63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0272989X8300300110","article-title":"Decision Maker 3.0. Improved decision analysis by personal computer","volume":"3","author":"Lau","year":"1983","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t20170623051943_CIT069C64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0025-6196(11)60837-9","article-title":"Patient selection for liver transplant: 1-year experience with 555 patients at a single center","volume":"83","author":"Aranda-Michel","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170623051943_CIT069C65","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1016\/j.transproceed.2011.08.076","article-title":"Social determinants of orthotopic liver transplantation candidacy: role of patient-related factors","volume":"43","author":"Kemmer","year":"2011","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20170623051943_CIT069C66","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/j.1572-0241.2001.04132.x","article-title":"Patients\u2019 values for health states associated with hepatitis C and physicians\u2019 estimates of those values","volume":"96","author":"Cotler","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170623051943_CIT069C67","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.164.21.2377","article-title":"Health values of patients with chronic hepatitis C infection","volume":"164","author":"Sherman","year":"2004","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170623051943_CIT069C68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Making"},{"key":"key\n\t\t\t\t20170623051943_CIT069C69","article-title":"A comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences","author":"Centers for Disease Control and Prevention","year":"2001"},{"key":"key\n\t\t\t\t20170623051943_CIT069C70","volume-title":"Hepatitis and liver cancer","author":"Committee on the Prevention and Control of Viral Hepatitis Infections","year":"2010"},{"key":"key\n\t\t\t\t20170623051943_CIT069C71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2893.2006.00785.x","article-title":"Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States","volume":"14","author":"Deuffic-Burban","year":"2007","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20170623051943_CIT069C72","first-page":"548","article-title":"HCV screening practices and prevalence in an MCO, 2000\u20132007","volume":"17","author":"Roblin","year":"2011","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t20170623051943_CIT069C73","article-title":"Recommendations for the identification of hepatitis C virus infection among persons born from 1945 through 1965","author":"Centers for Disease Control and Prevention","year":"2012"},{"key":"key\n\t\t\t\t20170623051943_CIT069C74","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/56\/10\/1382\/17851041\/cit069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T02:48:51Z","timestamp":1644288531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,7]]},"references-count":74,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,2,7]]},"published-print":{"date-parts":[[2013,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit069","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,7]]}}}